MTOR and Hodgkins lymphoma: While vorinostat/MLN0128 combination was most consistently promoting cell death, the toxicity of vorinostat/ panobinostat alone or in the combination with MLN0128 or other mTOR inhibitors has been reported in pre-clinical and clinical studies of T- cell [49] and Hodgkin's lymphoma [50], which warrants in vivo assessment in AML.